<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03452943</url>
  </required_header>
  <id_info>
    <org_study_id>TV50717-CNS-30046</org_study_id>
    <secondary_id>2016-000622-19</secondary_id>
    <nct_id>NCT03452943</nct_id>
  </id_info>
  <brief_title>Alternatives for Reducing Tics in TS: A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents.</brief_title>
  <acronym>ARTISTS</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products, R&amp;D Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the efficacy and safety of deutetrabenazine (TEV-50717) tablets
      for the reduction of motor and phonic tics associated with TS in children and adolescents 6
      through 16 years of age.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Total Tic Score (TTS) of the Yale Global Tic Severity Scale (YGTSS)</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>The YGTSS ranges from 0 - 50. A person who has no tics would have a score of 0. High score means a person has severe tics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Tourette Syndrome-Clinical Global Impression (TS-CGI) score</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Tourette Syndrome-Patient Global Impression of Impact (TS-PGII) score</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Gilles de la Tourette Syndrome - Quality of Life (GTS-QOL) physical/activities of daily living (ADL) subscale</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>TOURETTE SYNDROME</condition>
  <arm_group>
    <arm_group_label>TEV-50717</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TEV-50717 tablets taken twice daily for 12 weeks, includes a dose titration period and maintenance period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEV-50717</intervention_name>
    <description>6, 9, 12, 15, and 18 mg oral tablets</description>
    <arm_group_label>TEV-50717</arm_group_label>
    <other_name>deutetrabenazine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets taken twice daily for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is 6 to 16 years of age, inclusive

          -  Patient weighs at least 44 pounds (20 kg)

          -  The patient's active tics are causing distress or impairment

          -  Patient is able to swallow study medication whole

          -  Patient is in good general health

          -  Women/girls of childbearing potential whose male partners are of childbearing
             potential must use contraception for the duration of the study

               -  Additional criteria apply, please contact the investigator for more information

        Exclusion Criteria:

          -  Patient has a neurologic disorder other than Tourette syndrome (TS) that could obscure
             the evaluation of tics.

          -  Patient has a confirmed diagnosis of bipolar disorder, schizophrenia, or another
             psychotic disorder.

          -  Patient has clinically significant depression at screening or baseline.

          -  Patient has a history of suicidal intent or related behaviors within 2 years of
             screening.

          -  Patient has a history of a previous actual, interrupted, or aborted suicide attempt.

          -  Patient has a first-degree relative who has completed suicide.

          -  Patient has received comprehensive behavioral intervention for tics (CBIT) for TS or
             cognitive behavioral therapy (CBT) for obsessive-compulsive disorder (OCD) within 4
             weeks of screening.

          -  Patient has an unstable or serious medical illness at screening or baseline.

          -  Patient is pregnant or breastfeeding.

               -  Additional criteria apply, please contact the investigator for more information.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>TEVA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teva U.S. Medical Information</last_name>
    <phone>1-888-483-8279</phone>
    <email>USMedInfo@tevapharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Teva Investigational Site 046-0102</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>February 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2018</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tourette Syndrome</keyword>
  <keyword>adolescents</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Tourette Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetrabenazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

